2025
Fertile Ground for Mathematical Modeling: Therapeutic and Diagnostic Nanoparticle Transport in the Glomerulus
Richfield O, Cortez R, Navar L, Pober J, Zheng J, Saltzman W. Fertile Ground for Mathematical Modeling: Therapeutic and Diagnostic Nanoparticle Transport in the Glomerulus. Regenerative Engineering And Translational Medicine 2025, 1-17. DOI: 10.1007/s40883-025-00424-x.Peer-Reviewed Original ResearchChronic kidney diseaseGlomerular diseaseTreat glomerular diseasesKidney diseaseMaintenance of fluid balanceGlomerular filtration barrierTherapeutic optionsGlomerular hemodynamicsGlomerular pathologyFluid balanceGlomerular cellsGlomerular dysfunctionKidney failureRenal glomeruliGlomeruliHuman kidneyGlomerular capillariesNanoparticle transportUrine formationDiseaseFiltration barrierNP transportKidneyNP interactionsPhysiological maintenanceComprehensive characterization of interleukin-enhanced factor 2 (ILF2) in triple-negative breast cancer (TNBC).
Bustos M, Deshmukh S, Samec T, Wu S, Xiu J, Advani P, Jayachandran P, Mahtani R, Graff S, Lustberg M, Grumley J, Sledge G, Hoon D. Comprehensive characterization of interleukin-enhanced factor 2 (ILF2) in triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2025, 43: 1114-1114. DOI: 10.1200/jco.2025.43.16_suppl.1114.Peer-Reviewed Original ResearchTriple-negative breast cancerOverall survivalTumor microenvironmentBreast cancerManagement of triple-negative breast cancerInfiltration of NK cellsImmune suppressive tumor microenvironmentReal-world overall survivalSuppressive tumor microenvironmentPercentage of younger patientsDrug efflux genesImmune cell fractionsStem cell genesMann-Whitney U testKaplan-Meier estimatesL groupImmune checkpointsShorter OSNK cellsTNBC patientsTherapy resistanceTherapeutic optionsYounger patientsClinical outcomesFisher's exactClinicodemographic predictors of enrollment and outcomes in early phase oncology clinical trials in a diverse urban population.
Argulian A, Van Hyfte G, Baldwin E, Kulshrestha A, Lucas N, Wilk J, Wu K, Yuan M, Fazilov G, Fitzgerald L, Hapanowicz O, Osorio M, Cuevas J, Wawrzyniak A, Acuna-Villaorduna A, Zamarin D, Feng D, Galsky M, Marron T, Doroshow D. Clinicodemographic predictors of enrollment and outcomes in early phase oncology clinical trials in a diverse urban population. Journal Of Clinical Oncology 2025, 43: e13514-e13514. DOI: 10.1200/jco.2025.43.16_suppl.e13514.Peer-Reviewed Original ResearchEarly phase clinical trialsOverall survivalPerformance statusAnalyze factors associated with overall survivalFactors associated with overall survivalClinical trialsDose of study therapyDistance to treatment centerUnivariate Cox proportional hazards modelSolid tumor patientsECOG performance statusRetrospective chart reviewEffective novel therapiesPhase clinical trialsCox proportional hazards modelsProportional hazards modelAssociated with decreased likelihoodNon-white raceMedian OSECOG PSStudy therapyT patientsOncology clinical trialsMedian timeTherapeutic optionsClinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT
Gurnari C, Robin M, Adès L, Aljurf M, Almeida A, Duarte F, Bernard E, Cutler C, Della Porta M, De Witte T, DeZern A, Drozd-Sokolowska J, Duncavage E, Fenaux P, Gagelmann N, Garcia-Manero G, Haferlach C, Haferlach T, Hasserjian R, Hellström-Lindberg E, Jacoby M, Kulasekararaj A, Lindsley R, Maciejewski J, Makishima H, Malcovati L, Mittelman M, Myhre A, Ogawa S, Onida F, Papaemmanuil E, Passweg J, Platzbecker U, Pleyer L, Raj K, Santini V, Sureda A, Tobiasson M, Voso M, Yakoub-Agha I, Zeidan A, Walter M, Kröger N, McLornan D, Cazzola M. Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT. Blood 2025, 145: 1987-2001. PMID: 39970324, DOI: 10.1182/blood.2024025131.Peer-Reviewed Original ResearchAllo-HCTMolecular International Prognostic Scoring SystemGenomic profilingInternational Prognostic Scoring SystemAllogeneic hematopoietic cell transplantationAssociated with superior clinical outcomesMutant hematopoietic cellsNon-transplant therapiesPrognostic scoring systemHematopoietic cell transplantationClinical practiceTime of diagnosisSuperior clinical outcomesEstimate patient survivalIPSS-MAllo-HSCTCell transplantationExpert international panelPatient survivalPredisposition variantsTherapeutic optionsClinical outcomesCurative treatmentGenetic abnormalitiesHematopoietic cellsFGF21 Signaling Exerts Antifibrotic Properties during Pulmonary Fibrosis.
Ghanem M, Archer G, Justet A, Jaillet M, Vasarmidi E, Mordant P, Castier Y, Mal H, Cazes A, Poté N, Crestani B, Mailleux A. FGF21 Signaling Exerts Antifibrotic Properties during Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2025, 211: 486-498. PMID: 39637324, DOI: 10.1164/rccm.202311-2021oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisWild-type littermatesPlasma of patientsPulmonary fibrosisAntifibrotic propertiesIntratracheal injection of bleomycinDevelopment of pulmonary fibrosisDecreased fibrosis markersEffects of FGF21Increased sensitivity to bleomycinInjection of bleomycinPulmonary fibrosis developmentSensitivity to bleomycinDecrease of BaxConcentrations of FGF21Human lung fibroblastsTherapeutic optionsFibrosis markersAntifibrotic effectsControl subjectsInjury scoreIntratracheal injectionLiver fibrosisLung fibrogenesisFibroblast growth factorPericardial Disease: Contemporary Techniques and Management
Bae J, Saleh A, Hu J, Setaro J, Altin S. Pericardial Disease: Contemporary Techniques and Management. Current Treatment Options In Cardiovascular Medicine 2025, 27: 23. DOI: 10.1007/s11936-025-01081-7.Peer-Reviewed Original ResearchTreatment of recurrent pericarditisManagement of pericardial diseasesImmunosuppressive therapyRecurrent pericarditisTransthoracic echocardiographySignificant management challengeRefractory casesRecurrence ratePericardial diseaseTherapeutic optionsPharmacological therapyTherapeutic advancesClinical trialsTherapeutic approachesPoor visualizationDiagnostic precisionTherapyPatientsDiseaseDiagnostic techniquesSymptom burdenEvidence-basedPatient careTransthoracicEchocardiographyCharting the Course for Careers in Interventional Heart Failure: Training, Challenges, and Future Directions
Cheng R, Villela M, Masoumi A, Esposito M, Baran D, Rommel K, Fudim M, Mahfoud F, Lansky A, Burkhoff D, Kapur N. Charting the Course for Careers in Interventional Heart Failure: Training, Challenges, and Future Directions. Journal Of The Society For Cardiovascular Angiography & Interventions 2025, 4: 102569. PMID: 40231064, PMCID: PMC11993878, DOI: 10.1016/j.jscai.2025.102569.Peer-Reviewed Original ResearchTranscatheter valve therapiesHeart failureValve therapyCardiogenic shockCoronary interventionLow ejection fractionDevice-based therapiesTraining pathwaysComplexity of therapeutic optionsEndomyocardial biopsyEjection fractionImplantable pressure sensorTherapeutic optionsHeart transplantationAdvanced HFAtrial pressureImprove outcomesCardiology trainingExercise Pulmonary Hypertension and Beyond: Insights in Exercise Pathophysiology in Pulmonary Arterial Hypertension (PAH) from Invasive Cardiopulmonary Exercise Testing
Tarras E, Singh I, Kreiger J, Joseph P. Exercise Pulmonary Hypertension and Beyond: Insights in Exercise Pathophysiology in Pulmonary Arterial Hypertension (PAH) from Invasive Cardiopulmonary Exercise Testing. Journal Of Clinical Medicine 2025, 14: 804. PMID: 39941482, PMCID: PMC11818252, DOI: 10.3390/jcm14030804.Peer-Reviewed Original ResearchInvasive cardiopulmonary exercise testingPulmonary arterial hypertensionCardiopulmonary exercise testingArterial hypertensionAssociated with pulmonary vascular remodelingExercise testRight heart failureExercise pulmonary hypertensionPulmonary vascular remodelingPulmonary hypertensionProgressive diseasePulmonary vasculatureTherapeutic optionsExercise pathophysiologyHigh morbidityHeart failureEarly diagnosisVascular remodelingTherapeutic approachesPersonalized treatmentHypertensionDisease subtypesDiagnosisSkeletal muscleDiseaseSalidroside Improves Oocyte Competence of Reproductively Old Mice by Enhancing Mitophagy
Gu J, Hua R, Wu H, Guo C, Hai Z, Xiao Y, Yeung W, Liu K, Babayev E, Wang T. Salidroside Improves Oocyte Competence of Reproductively Old Mice by Enhancing Mitophagy. Aging Cell 2025, 24: e14475. PMID: 39789811, PMCID: PMC12073897, DOI: 10.1111/acel.14475.Peer-Reviewed Original ResearchReproductively old miceImprove oocyte qualityOocyte qualityOld miceDecline of oocyte qualityDevelopmental competence of oocytesReproductively older womenCompetence of oocytesKnowledge of therapeutic optionsOocyte competenceDevelopmental competenceTherapeutic optionsMaternal ageSpindle/chromosome structureAssisted reproductionOld femaleMiceOocytesOlder womenNatural fertilityFemale fertilityMitochondrial function
2024
New potential ligand-receptor axis involved in tissue repair as therapeutic targets in progressive multiple sclerosis
Carrera Silva E, Correale J, Rothlin C, Ortiz Wilczyñski J. New potential ligand-receptor axis involved in tissue repair as therapeutic targets in progressive multiple sclerosis. Journal Of Pharmacology And Experimental Therapeutics 2024, 392: 100029. PMID: 39892997, DOI: 10.1124/jpet.124.002254.Peer-Reviewed Original ResearchProgressive multiple sclerosisLigand-receptor axisNeuroprotective therapeutic strategiesMultiple sclerosisTissue repairTherapeutic strategiesRefractory to current treatmentsIncreasing preclinical evidenceStages of multiple sclerosisEarly stages of multiple sclerosisAnti-inflammatoryPromote tissue repairTissue repair processPreclinical evidenceTherapeutic optionsReceptor axisReceptor/ligand pairsCurrent treatmentPathogenic mechanismsMS diseaseBenefit patientsTherapeutic interventionsTherapeutic targetSignaling AxisEra of omicsA Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy
Hofmeister C, Gupta V, Joseph N, Lonial S, Dhodapkar M, Nooka A, Kaufman J. A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy. Blood 2024, 144: 4672. DOI: 10.1182/blood-2024-203485.Peer-Reviewed Original ResearchAL amyloidosisPlasma cell-directed therapyHigh-sensitivity troponin THematological complete remissionSevere cardiac involvementCell-directed therapiesPoor performance statusMonths of treatmentEnd-stage cardiomyopathyDaratumumab monotherapyComplete remissionCardiac involvementNT-proBNPPerformance statusAmyloid cardiomyopathyTherapeutic optionsSevere cardiomyopathyHeart transplantationStage 3bDirected therapyDiagnosed patientsEuropean trialsClinical consequencesTroponin TTargeted treatmentAdvances in predicting breast cancer driver mutations: Tools for precision oncology (Review)
Hao W, Rajendran B, Cui T, Sun J, Zhao Y, Palaniyandi T, Selvam M. Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review). International Journal Of Molecular Medicine 2024, 55: 6. PMID: 39450552, PMCID: PMC11537269, DOI: 10.3892/ijmm.2024.5447.Peer-Reviewed Original ResearchConceptsDisease-free survivalBreast cancerPrecision medicine approachAvailability of high-throughput sequencingPrecision oncologyTherapeutic optionsDriver mutationsDisease-free survival of patientsCancer driver gene identificationDriver gene identificationMedicine approachHigh-throughput sequencingSurvival of patientsTargeted therapeutic optionsFraction of patientsCancer driver mutationsTargeted therapeutic approachesBreast cancer treatmentIdentification of driver mutationsBreast cancer mutationsModern era of medicineCancer-specific biomarkersGene identificationCancer DatabaseCancer mutationsImmune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups
Leone A, Mai A, Fong K, Yap D, Kato K, Smyth E, Moehler M, Seong J, Sundar R, Zhao J, Pietrantonio F. Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups. ESMO Open 2024, 9: 103962. PMID: 39426081, PMCID: PMC11533044, DOI: 10.1016/j.esmoop.2024.103962.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCombined positive scoreBenefit of immune checkpoint inhibitorsCheckpoint inhibitorsOS benefitOverall survivalAnti-programmed cell death protein 1Kaplan-Meier (KM) plotsEfficacy of immune checkpoint inhibitorsFirst-line immune checkpoint inhibitorsPD-L1 combined positive scoreProgrammed death ligand 1 subgroupsCell death protein 1Programmed death-ligand 1Patient-level meta-analysesPatient-Level Meta-AnalysisDeath-ligand 1Advanced gastroesophageal adenocarcinomaRandomized clinical trialsCheckMate-649KEYNOTE-062Gastroesophageal adenocarcinomaTherapeutic optionsClinical trialsKM plotsNavigating new norms: Addiction specialists' perspectives on opioid use disorder treatments and policy challenges in the fentanyl era
Weleff J, Christian N, Wang J, Singh M, De Aquino J, Saxon A, Vassallo G. Navigating new norms: Addiction specialists' perspectives on opioid use disorder treatments and policy challenges in the fentanyl era. American Journal On Addictions 2024, 34: 85-92. PMID: 39364597, PMCID: PMC11673400, DOI: 10.1111/ajad.13653.Peer-Reviewed Original ResearchSlow-release oral morphineOpioid use disorderBarriers to OUD treatmentAddiction specialistsOpioid use disorder managementUse disorderOUD treatmentThird-line monotherapyFisher's exact testOpioid use disorder treatmentOff-label prescribingOral morphineAgonist opioidsOpioid agonistsOpioid-related overdoseTherapeutic optionsWithdrawal symptomsNovel therapiesExact testOpioidMOUD prescribingSynthetic opioidsClinical practiceClinical approachCompare respondent characteristicsIdentification of FGFR4 as a regulator of myofibroblast differentiation in pulmonary fibrosis
Ghanem M, Justet A, Jaillet M, Vasarmidi E, Boghanim T, Hachem M, Vadel A, Joannes A, Mordant P, Balayev A, Adams T, Mal H, Cazes A, Poté N, Mailleux A, Crestani B. Identification of FGFR4 as a regulator of myofibroblast differentiation in pulmonary fibrosis. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2024, 327: l818-l830. PMID: 39350729, DOI: 10.1152/ajplung.00184.2023.Peer-Reviewed Original ResearchWild type littermatesFibroblast growth factorMurine embryonic fibroblastsEndothelin-1Pulmonary fibrosisFGFR4 inhibitionBleomycin-Induced Pulmonary FibrosisIn vitroMyofibroblast differentiationBleomycin-induced lung fibrosisPulmonary fibrosis in vivoTGF-bLung fibroblastsPro-fibrotic propertiesProtein levelsIn vivoAnti-fibrotic propertiesFibrosis in vivoRegulation of myofibroblast differentiationDevelopment of bleomycin-induced lung fibrosisWT miceTherapeutic optionsHuman lung fibroblastsIPF lungsLung fibrosisNovel treatment for PXE: Recombinant ENPP1 enzyme therapy
Jacobs I, Obiri-Yeboah D, Stabach P, Braddock D, Li Q. Novel treatment for PXE: Recombinant ENPP1 enzyme therapy. Molecular Therapy 2024, 32: 3815-3820. PMID: 39342427, PMCID: PMC11573614, DOI: 10.1016/j.ymthe.2024.09.028.Peer-Reviewed Original ResearchAbcc6<sup>-/-</sup> micePseudoxanthoma elasticumAbcc6<sup>-/-</sup> mouse model of pseudoxanthoma elasticumPPI levelsMouse model of pseudoxanthoma elasticumModel of pseudoxanthoma elasticumEnzyme therapyEctopic calcificationPlasma PPi levelsMuzzle skinDose-dependent elevationHepatic efflux transportersPrevent ectopic calcificationPlasma PPiABCC6 geneATP secretionTherapeutic optionsDose-dependentlyEfflux transportersInactivating mutationsENPP1 activitySubcutaneous injectionWeeks of ageNovel treatmentCalcification disordersGly-β-MCA is a potent anti-cholestasis agent against “human-like” hydrophobic bile acid-induced biliary injury in mice
Hasan M, Wang H, Luo W, Clayton Y, Gu L, Du Y, Palle S, Chen J, Li T. Gly-β-MCA is a potent anti-cholestasis agent against “human-like” hydrophobic bile acid-induced biliary injury in mice. Journal Of Lipid Research 2024, 65: 100649. PMID: 39306039, PMCID: PMC11526081, DOI: 10.1016/j.jlr.2024.100649.Peer-Reviewed Original ResearchUrsodeoxycholic acid treatmentUrsodeoxycholic acidPortal fibrosisHepatobiliary injuryClinically relevant dosesMuricholic acidsChronic liver diseaseBile acidsEndogenous bile acidsHydrophobic bile acidsPortal inflammationBile acid pool compositionLithocholic acidTherapeutic optionsBiliary injuryKO miceLine drugsBile acid pool sizeSerum transaminasesBile acid poolRelevant dosesDuctular reactionLiver diseaseCholestasisCholestasis modelThe protein disulfide isomerase A3 and osteopontin axis promotes influenza‐induced lung remodelling
Kumar A, Mark Z, Carbajal M, DeLima D, Chamberlain N, Walzer J, Ruban M, Chandrasekaran R, Daphtary N, Aliyeva M, Poynter M, Janssen‐Heininger Y, Bates J, Alcorn J, Britto C, Dela Cruz C, Jegga A, Anathy V. The protein disulfide isomerase A3 and osteopontin axis promotes influenza‐induced lung remodelling. British Journal Of Pharmacology 2024, 181: 4610-4627. PMID: 39118388, DOI: 10.1111/bph.16511.Peer-Reviewed Original ResearchProtein disulfide isomerase A3Secreted Phosphoprotein 1Lung fibrosisLung remodelingFibrotic remodelingViral infectionAssociated with pulmonary fibrosisInfluenza-infected patientsMacrophage colony-stimulating factorFibrotic lung remodelingSPP1 expressionRespiratory viral infectionsImproved oxygen saturationColony-stimulating factorLung fibrotic remodelingDebilitating clinical sequelaeIAV infectionFibrotic sequelaeClinical sequelaeTherapeutic optionsPulmonary fibrosisRetrospective analysisNeutralizing antibodiesCell culture modelHealthy controlsRenal Denervation for the Treatment of Hypertension: A Scientific Statement From the American Heart Association
Cluett J, Blazek O, Brown A, East C, Ferdinand K, Fisher N, Ford C, Griffin K, Mena-Hurtado C, Sarathy H, Vongpatanasin W, Townsend R, Disease O. Renal Denervation for the Treatment of Hypertension: A Scientific Statement From the American Heart Association. Hypertension 2024, 81: e135-e148. PMID: 39101202, DOI: 10.1161/hyp.0000000000000240.Peer-Reviewed Original ResearchRenal denervationBlood pressureEfficacy of renal denervationUS Food and Drug AdministrationRandomized clinical studyRenal sympathetic nervesNovel treatment strategiesBlood pressure control ratesLonger-term efficacyIndividual patient responseLowering blood pressureFood and Drug AdministrationSpectrum of hypertensionTreatment of hypertensionControl blood pressureUncontrolled blood pressureMultiple ongoing studiesCatheter-based proceduresAmerican Heart AssociationHigh blood pressureTherapeutic optionsSafety profileCardiovascular morbidityControl rateHypertension specialistsA call to address penicillin allergy labels in patients with hematopoietic stem cell transplants: How to avoid rash decisions
Belmont A, Stone C, Guyer A, Edelman E, Trubiano J. A call to address penicillin allergy labels in patients with hematopoietic stem cell transplants: How to avoid rash decisions. Transplant Infectious Disease 2024, 26: e14350. PMID: 39101669, PMCID: PMC11502247, DOI: 10.1111/tid.14350.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationStem cell transplantationPenicillin allergy labelMultidrug-resistant infectionsPenicillin allergyCell transplantationAllergy labelsAssociated with more severe infectionsReported penicillin allergyRisk-stratify patientsMore severe infectionsPoint-of-care assessmentBeta-lactam antibioticsClinical decision toolTolerate penicillinsAssociated with useDelabel patientsTherapeutic optionsEvaluating patientsSevere infectionsAlternative antibioticsOral challengeClinical care settingsClostridium difficilePatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply